Portal de Periódicos da CAPES

Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area

2015; Nature Portfolio; Volume: 18; Issue: 3 Linguagem: Inglês

10.1038/nn.3932

1546-1726

Ja Wook Koo, Michelle S. Mazei‐Robison, Quincey LaPlant, Gábor Egervári, Kevin M. Braunscheidel, Danielle N. Adank, Deveroux Ferguson, Jian Feng, HaoSheng Sun, Kimberly N. Scobie, Diane Damez-Werno, Efrain Ribeiro, Catherine J. Peña, Deena M. Walker, Rosemary C. Bagot, Michael E. Cahill, Sarah Anderson, Benoît Labonté, Georgia E. Hodes, Heidi A. Browne, Benjamin Chadwick, Alfred J. Robison, Vincent Vialou, Caroline Dias, Zachary S. Lorsch, Ezekiell Mouzon, Mary Kay Lobo, David Dietz, Scott J. Russo, Rachael L. Neve, Yasmin L. Hurd, Eric J. Nestler,

Protein Degradation and Inhibitors

Brain-derived neurotrophic factor (BDNF) has a crucial role in modulating neural and behavioral plasticity to drugs of abuse. We found a persistent downregulation of exon-specific Bdnf expression in the ventral tegmental area (VTA) in response to chronic opiate exposure, which was mediated by specific epigenetic modifications at the corresponding Bdnf gene promoters. Exposure to chronic morphine increased stalling of RNA polymerase II at these Bdnf promoters in VTA and altered permissive and repressive histone modifications and occupancy of their regulatory proteins at the specific promoters. Furthermore, we found that morphine suppressed binding of phospho-CREB (cAMP response element binding protein) to Bdnf promoters in VTA, which resulted from enrichment of trimethylated H3K27 at the promoters, and that decreased NURR1 (nuclear receptor related-1) expression also contributed to Bdnf repression and associated behavioral plasticity to morphine. Our findings suggest previously unknown epigenetic mechanisms of morphine-induced molecular and behavioral neuroadaptations.